Comparing bivalent and quadrivalent human papillomavirus vaccines: Economic evaluation based on transmission model

BMJ (Online)

Volumn 343, Issue 7825, 2011, Pages

  Jit, Mark ^a   Chapman, Ruth ^a   Hughes, Owain ^b   Choi, Yoon Hong ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PREVENTION; CHILD; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG INDICATION; FEMALE; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; MALE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; SENSITIVITY ANALYSIS; UNITED KINGDOM; UTERINE CERVIX CANCER; VIRUS TRANSMISSION; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; ECONOMICS; IMMUNOLOGY; MIDDLE AGED; THEORETICAL MODEL;

ADOLESCENT; ADULT; AGED; CHILD; CONDYLOMATA ACUMINATA; COST-BENEFIT ANALYSIS; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; YOUNG ADULT;

EID: 80054831192     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d5775     Document Type: Article

References (71)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65. (Pubitemid 34293391)
2. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24 (suppl 3):S3-11-S3/25.
3. Clifford, G. The growing evidence of an epidemiological link between oral cancers and HPV. Presented at EUROGIN 2010, Monte Carlo, Monaco, Feb 20, 2010.
4. Bosch FX, De Sanjose S. Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003;3-13.
5. Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493.
6. Gissmann L, Diehl V, Schultz-Coulon HJ, zur HH. Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. J Virol 1982;44:393-400. (Pubitemid 12020931)
7. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-702. (Pubitemid 46783792)
8. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011;364:401-11.
9. Kreimer AR, González P, Katki HA, Porras C, Schiffman M, Rodriguez AC, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011;12:862-70.
10. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-35.
11. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14.
12. Tjalma W, Paavonen J, Naud P, Wheeler C, Chow S-N, Apter D, et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPV-naive population. Presentation at the 16th International Meeting of the European Society for Gynaecological Oncology, Belgrade, October 11-14, 2009. Int J Gynecol Cancer 2009;19:1-1024.
13. Romanowski B. Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines. Hum Vaccin 2011;7(2) [epub ahead of print].
14. Kim JJ. Human papillomavirus vaccination in the UK. BMJ 2008;337:a842.
15. Sheridan A, White J. Annual HPV vaccine coverage in England in 2009/2010. Report commissioned by the Department of Health. www.dh.gov.uk/prod-consum-dh/ groups/dh-digitalassets/documents/digitalasset/dh-123826.pdf.
16. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008;337:a769.
17. Howell-Jones R, Bailey A, Beddows S, Sargent A, De Silva N, Wilson G, et al. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer 2010;103:209-16.
18. Woodhall SC, Jit M, Soldan K, Kinghorn G, Gilson R, Nathan M, et al. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect 2011 [epub ahead of print].
19. Desai S, Wetten S, Woodhall SC, Peters L, Hughes G, Soldan K. Genital warts and the cost of care in England. Sex Transm Inf [forthcoming].
20. Hughes OR, Tsikoudas A, Auerbach R, Barr GD, Bateman N, Blarney S, et al. The burden of recurrent respiratory papillomatosis in the United Kingdom: results from the BAPO and ENT-UK National Survey. Clin Otolaryngol [forthcoming].
21. Chapman R, Soldan K, Jit M. Modelling borderline and mild dysplasia associated with HPV 6 and 11 infection. Vaccine 2011;29:2881-6.
22. Choi Y, Jit M, Gay N. Unmasking HPV genotypes as impact of HPV vaccination. Poster P-29.44 presented at the International Papillomavirus Conference, Malmo, Sweden, May 8-14, 2009.
23. Department of Health. Key vaccine information: HPV . www.dh.gov.uk/en/ Publichealth/Immunisation/Keyvaccineinformation/DH-104010
24. Curtis L. Unit costs of health and social care 2009 . Personal Social Services Research Unit, University of Kent, 2009.
25. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal . NICE, 2008.
26. Office for National Statistics. Cancer statistics 2007: registrations series MB1 No 37 . www.statistics.gov.uk/downloads/theme-health/MB1-38/Table-1. xls.
27. Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995;33:2058-63.
28. Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999;37:3316-22. (Pubitemid 29455226)
29. Sturegard E, Johnsson A, Gustafsson E, Dillner J. [Condyloma typing important for follow up of HPV vaccination. A condyloma reporting project.] Lakartidningen 2008;105:3648-50.
30. Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 2010;28:4091-102.
31. De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010;28:6247-55.
32. Steben M. Update on Gardasil (quadrivalent human papillomavirus [HPV] 6/11/16/18 vaccine) clinical trial efficacy results. Presented at EUROGIN 2010, Monte Carlo, Monaco, Feb 17-20, 2010.
33. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931-9. (Pubitemid 46843434)
34. David MP, van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009;115:S1-6.
35. Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008;26 (suppl 10):K53-61.
36. van de Velde N, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. Vaccine 2010;28:5473-84.
37. Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006;95:56-61. (Pubitemid 43980554)
38. Quint W, Molijn A, Colau B, van de Sandt M, Jenkins D. One HPV virus, one lesion as determined by LCM/PCR technology. Abstract 06.04. 25th International Papillomavirus Conference, Malmo, Sweden, 2009.
39. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009;101:475-87.
40. Franco E. Is type replacement something to worry about: yes or no? Oral presentation at EUROGIN 2010, Monte Carlo, Monaco, Feb 17-20, 2010.
41. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary 59 . BMA, 2010.
42. Martin-Hirsch P, Rash B, Martin A, Standaert B. Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales. BJOG 2007;114:408-15. (Pubitemid 46393298)
43. Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004;8(20):iii, 1-78.
44. Brown RE, Breugelmans JG, Theodoratou D, Benard S. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006;22:663-70.
45. Institute of Medicine. Vaccines for the 21st century: a tool for decisionmaking . National Academy Press, 2000.
46. Myers ER, Green S, Lipkus I. Patient preferences for health states related to HPV infection: visual analog scales vs time trade-off elicitation. 21st International Papillomavirus Conference and Clinical Workshop, Mexico City, Mexico.
47. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998;36:778-92. (Pubitemid 128454315)
48. Office for National Statistics. Cancer survival, England, patients diagnose 2001-2006 and followed up to 2007: one-year and five-year relative survival for 21 common cancers, by sex and age. www.statistics.gov.uk/downloads/ theme-health/cancer-survival-Eng-2001-2006.pdf.
49. Klee M, Thranov I, Machin D. Life after radiotherapy: the psychological and social effects experienced by women treated for advanced stages of cervical cancer. Gynecol Oncol 2000;76:5-13. (Pubitemid 30048312)
50. Klee M, Thranov I, Machin PD. The patients' perspective on physical symptoms after radiotherapy for cervical cancer. Gynecol Oncol 2000;76:14-23. (Pubitemid 30048313)
51. Korfage IJ, Essink-Bot ML, Mols F, Poll-Franse L, Kruitwagen R, van Ballegooijen M. Health-related quality of life in cervical cancer survivors: a population-based survey. Int J Radiat Oncol Biol Phys 2009;73:1501-9.
52. Rogers SN, Miller RD, Ali K, Minhas AB, Williams HF, Lowe D. Patients' perceived health status following primary surgery for oral and oropharyngeal cancer. Int J Oral Maxillofac Surg 2006;35:913-9. (Pubitemid 44542560)
53. Office for National Statistics. One- and five-year surival of patients diagnosed in 1991-95 and 1996-99: less common cancers, sex and age, England and Wales . www.statistics.gov.uk/statbase/Expodata/Spreadsheets/D8904.xls.
54. Jeffreys M, Rachet B, McDowell S, Habib AG, Lepage C, Coleman MP. Survival from rectal and anal cancers in England and Wales, 1986-2001. Eur J Cancer 2006;42:1434-40. (Pubitemid 44183847)
55. Wolstenholme JL,Whynes DK. Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer 1998;34:1889-93. (Pubitemid 28535437)
56. Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008;198:500-7.
57. De Rijke JM, van der Putten HW, Lutgens LC, Voogd AC, Kruitwagen RF, van Dijck JA, et al. Age-specific differences in treatment and survival of patients with cervical cancer in the southeast of the Netherlands, 1986-1996. Eur J Cancer 2002;38:2041-7.
58. Bishai D, Kashima H, Shah K. The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2000;126:935-9. (Pubitemid 30658290)
59. Chadha NK, Allegro J, Barton M, Hawkes M, Harlock H, Campisi P. The quality of life and health utility burden of recurrent respiratory papillomatosis in children. Otolaryngol Head Neck Surg 2010;143:685-90.
60. Ilmarinen T, Nissila H, Rihkanen H, Roine RP, Pietarinen-Runtti P, Pitkaranta A, et al. Clinical features, health-related quality of life, and adult voice in juvenile-onset recurrent respiratory papillomatosis. Laryngoscope 2011;121:846-51.
61. Reeves WC, Ruparelia SS, Swanson KI, Derkay CS, Marcus A, Unger ER. National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003;129:976-82. (Pubitemid 37087659)
62. Stern PL. For debate: that Australia should consider changing to the bivalent vaccine. Sex Health 2010;7:238-41.
63. Wain G. For debate: that Australia should continue using the quadrivalent vaccine. Sex Health 2010;7:235-7.
64. Morris SR. HPV vaccine strategies: the cost of HPV and the choice of vaccine. Sex Transm Infect 2009;85:315-6.
65. Hawkes N. Anger over Department of Health choice of cheaper cancer vaccine. Times 2008 July 18.
66. Haas M, Ashton T, Blum K, Christiansen T, Conis E, Crivelli L, et al. Drugs, sex, money and power: an HPV vaccine case study. Health Policy 2009;92:288-95.
67. Dee A, Howell F. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health 2010;20:213-9.
68. Brisson M, van de Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007;25:5399-408. (Pubitemid 46977529)
69. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008;359:821-32.
70. De Kok IM, Habbema JD, van Rosmalen J, van Ballegooijen M. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? Eur J Cancer 2011;47:428-35.
71. Demarteau N, Standaert B. Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer. J Med Econ 2010;13:324-38.